OPRK1 and Alzheimer disease: A study has shown that the peripheral kappa opioid receptor agonist, difelikefalin, can improve itching and quality of life in patients with AD, and another study is evaluating it as an adjunctive treatment to topical corticosteroid in AD patients (NCT05387707) [32].